Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF versus no immunosuppression in adults with limited cutaneous systemic sclerosis
2019-004139-21Phase 2Unknown
- Sponsor
- University College London
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mycophenolate mofetil in limited scleroderma and systemic sclerosis (SSc) (2 arms), sponsored by University College London. Primary endpoints: Recruitment feasibility, Endpoint viability for an event-driven trial and 1 more. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
limited sclerodermasystemic sclerosis (SSc)
Beyond the preview
Go deeper on 2019-004139-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004139-21.